Original StudyCOMBINED VITRECTOMY AND INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANTZheng, Andrew BS; Chin, Eric K. MD; Almeida, David R. P. MD, MBA, PhD; Tsang, Stephen H. MD, PhD; Mahajan, Vinit B. MD, PhD Author Information *The Bernard and Shirlee Brown Glaucoma Laboratory, Departments of Ophthalmology, Pathology and Cell Biology, Institute of Human Nutrition, College of Physicians and Surgeons, Columbia University, New York, New York; †Omics Laboratory, Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa; ‡Vitreoretinal Service, Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa; §Retina Consultants of Southern California, Redlands, California; and ¶VitreoRetinal Surgery, Minneapolis, Minnesota. Reprint requests: Vinit B. Mahajan, MD, PhD, Department of Ophthalmology, The University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242; e-mail: [email protected] V. B. Mahajan is supported by NIH Grants K08EY020530, R01EY016822, the Doris Duke Charitable Foundation Grant #2013103, and Research to Prevent Blindness (New York, NY). The remaining authors have no financial/conflicting interests to disclose. V. B. Mahajan had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: All authors. Acquisition of data: All authors. Analysis and interpretation of data: All authors. Drafting of the manuscript: A. Zheng and V. B. Mahajan. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: A. Zheng and V. B. Mahajan. Obtained funding: V. B. Mahajan. Administrative, technical, and material support: V. B. Mahajan. Study supervision: V. B. Mahajan. Retina: November 2016 - Volume 36 - Issue 11 - p 2087-2092 doi: 10.1097/IAE.0000000000001063 Buy Metrics AbstractIn Brief Purpose: To evaluate the safety and efficacy of combining intravitreal dexamethasone implantation (Ozurdex) with pars plana vitrectomy (PPV). Methods: A retrospective review was conducted on cases where Ozurdex injection was performed in the operating room in conjunction with pars plana vitrectomy. Our primary outcome measure was the presence of surgical complications in the perioperative and 3-month postoperative window. We also measured visual acuity, intraocular pressure (IOP), and macular edema at baseline, one, and 3 months after surgery. Results: Fifteen eyes in 14 cases were reviewed. There were no complications intraoperatively or at 1-month postoperatively. Two patients (2 eyes) with prior retinal detachment developed proliferative vitreoretinopathy and redetachment at 3 months. Visual acuity improved in 7 of 15 eyes, and an average improvement of 2 lines was achieved for the entire cohort. There was no overall change in intraocular pressure although 1 patient developed an increase in intraocular pressure >5 mmHg. Five of 9 patients with baseline macular edema experienced improvement or resolution at 3 months. Conclusion: Intraoperative Ozurdex in combination with PPV may be safe and effective in treating macular edema caused by many different underlying diseases. Dexamethasone implant (Ozurdex) may be indicated for several different conditions in patients who also require pars plana vitrectomy to improve corticosteroid efficacy in vitrectomized eyes. In this retrospective review of 15 cases, the authors found that concurrent, intraoperative Ozurdex combined with vitrectomy was safe and effective in treating macular edema because of diabetic retinopathy, retinal vein occlusion, and posterior uveitis. © 2016 by Ophthalmic Communications Society, Inc.